Qichen, Scientist, CRISPR-X at CRISPR Therapeutics

Qichen

Scientist, CRISPR-X at CRISPR Therapeutics | Boston, Massachusetts, United States

Profile last verified October 2026
Higher Education Verified Profile Boston, Massachusetts, United States Rice University
Verified

Personal Email

***@gmail.com

Personal • High Confidence

Phone Number

(413) ***-*771

United States • Phone

Free account · No credit card · 5 profiles/month

Qichen Socials
Qichen Work Experience

Scientist, CRISPR-X at CRISPR Therapeutics in June 2024 - Present

Scientist, Genome Engineering at Colossal Biosciences in May 2023 - May 2024

Graduate Research Fellow at Rice University in July 2019 - May 2023

See more See less

Research Associate at Tsinghua University in August 2017 - April 2019

Undergraduate Researcher at University of Science and Technology of China in September 2013 - June 2017

Qichen Education

Rice University, Doctor of Philosophy - PhD, November 2026

University of Science and Technology of China, Bachelor of Science - BS, November 2026

Qichen Skills
Gene Editing Molecular Biology Genetics Research Public Speaking Presentation Skills Communication Teaching Problem Solving Gene Therapy Oncology Molecular Cloning Organization Skills Time Management Leadership Life Sciences AAV Lentivirus Next-Generation Sequencing RNAi Bioinformatics Reverse Transcription Polymerase Chain Reaction (RT-PCR) Polymerase Chain Reaction (PCR) Real-Time Polymerase Chain Reaction (qPCR) Flow Cytometry Biochemistry Transfection Data Analysis Cell Culture
About Qichen’s Current Company
CRISPR Therapeutics

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

Discover more about CRISPR Therapeutics
Qichen’s Colleagues
Hannah Nierle

Hannah Nierle

Greater Boston

Clinical Trial Manager at CRISPR Therapeutics

Clinical Trial Manager at CRISPR Therapeutics
(August 2025 – Present)

Kiera Fallon

Kiera Fallon

Boston, Massachusetts, United States

Research Associate at CRISPR Therapeutics || MBA Candidate at Questrom School of Business

Research Associate II at CRISPR Therapeutics
(June 2024 – Present)

Sammy Hankaoui

Sammy Hankaoui

Greater Boston

Cell Therapy at CRISPR Therapeutics || MBA Candidate at WPI

Cell Therapy at CRISPR Therapeutics
(July 2023 – Present)

Aj Silver

Aj Silver

Suffolk County, Massachusetts, United States

Senior Vice President Finance

Senior Vice President Finance at CRISPR Therapeutics
(January 2025 – Present)

MD

Marylee Dequeant

Greater Boston

Executive Director, Head of In Vivo Research | Immuno-Oncology | Cell and Gene Therapy | CRISPR | LNP Delivery | CAR-T | CTA and IND Strategy | Cross-Functional Leadership | Regulatory Interactions | AAV | Liver | Eye |

Head of In Vivo Research, Executive Director, and Immuno-Oncology Lead at CRISPR Therapeutics
(July 2024 – Present)

Aamir Mir

Aamir Mir

Cambridge, Massachusetts, United States

Senior Director at CRISPR Therapeutics

Senior Director, CRISPR-X at CRISPR Therapeutics
(Jul 2025 – Present)

Search similar profiles
Frequently asked questions about Qichen

What is Qichen email address?

Email Qichen at [email protected] and [email protected]. This email is the most updated Qichen's email found in 2026.

How to contact Qichen?

To contact Qichen send an email to [email protected] or [email protected]. (updated on August 31, 2025)

What company does Qichen work for?

Qichen works for CRISPR Therapeutics.

What is Qichen's role at CRISPR Therapeutics?

Qichen is Scientist, CRISPR-X

What industry does Qichen work in?

Qichen works in the Higher Education industry.

Find anyone, anywhere
with ContactOut today

Making remote or global hires? Connecting
with key decision-makers? We can help.

  • 40 emails / month
  • 3 phone numbers / month
  • Works on standard LinkedIn only
  • Work emails, personal emails,
    mobile numbers
* 1 user per company limit

No credit card required

Try ContactOut for Free